PASSAGE BIO, INC. Increase (Decrease) in Accrued Liabilities
PASSAGE BIO, INC. (PASG) reported Increase (Decrease) in Accrued Liabilities of $3.87 million for the 6-month period ending 2020-06-30, per its 10-Q filed 2020-08-13.
Discontinued › Cash Flow
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2020-08-13
- PASSAGE BIO, INC. increase (decrease) in accrued liabilities for the quarter ending 2020-06-30 was $4.29M, a 435.41% increase year-over-year.
- PASSAGE BIO, INC. increase (decrease) in accrued liabilities for the quarter ending 2020-03-31 was -$426.00K, a 213.00% decline year-over-year.
- PASSAGE BIO, INC. increase (decrease) in accrued liabilities for the quarter ending 2019-06-30 was $802.00K.
- PASSAGE BIO, INC. increase (decrease) in accrued liabilities for the quarter ending 2019-03-31 was $377.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month |
|---|---|---|
| 2020-06-30 | $4.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $3.87M 10-Q · filed 2020-08-13 |
| 2020-03-31 | -$426.00K 10-Q · filed 2020-05-11 | |
| 2019-06-30 | $802.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $1.18M 10-Q · filed 2020-08-13 |
| 2019-03-31 | $377.00K 10-Q · filed 2020-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |